University of Genoa, Italy.
IRCCS Istituto Giannina Gaslini, Genoa, Italy.
J Infect Public Health. 2021 Oct;14(10):1560-1562. doi: 10.1016/j.jiph.2021.06.020. Epub 2021 Jul 5.
As part of the fight against SARS CoV2 infection, vaccination program for health workers at Giannina Gaslini pediatric hospital (IGG) in Genoa, Italy, started on December 2020. We evaluated the anti-Spike protein response in healthcare workers after a complete vaccination scheme of 2 doses spaced by 3 weeks.
Immunoglobulin class G (IgG) against SARS-CoV-2 spike RBD were detected by means of a chemiluminescence immunoassay for quantitative IgG antibodies using Maglumi SARS-CoV-2-S-RBD IgG kit during the 3rd week after vaccination completion.
IgG anti SARS-CoV-2 spike protein were detected in 99.88% of 1765 healthcare workers 3 weeks after 2nd dose of BNT162b2. Higher median IgG values were observed in younger subjects (807 UA/mL in under 30 vs 429 UA/mL in over 60; p < 0.001) and those with previous COVID-19 (1284 vs 574 UA/mL; p < 0.001).
BNT162b2 is effective in inducing anti SARS-CoV-2 antibodies even in real-life setting. The higher antibody title observed in workers with a previous documented SARS CoV2 infection confirms the possibility to carry out only one dose of BNT162b2 in a context of vaccines shortage.
作为抗击 SARS-CoV2 感染的一部分，意大利热那亚 Giannina Gaslini 儿科医院（IGG）的卫生工作者的疫苗接种计划于 2020 年 12 月开始。我们评估了卫生工作者在完成 2 剂、间隔 3 周的完整疫苗接种方案后对 Spike 蛋白的抗体反应。
在接种完成后的第 3 周，使用 Maglumi SARS-CoV-2-S-RBD IgG 试剂盒通过化学发光免疫分析法检测针对 SARS-CoV-2 刺突 RBD 的免疫球蛋白 G（IgG）。
在接受 2 剂 BNT162b2 后 3 周，1765 名卫生工作者中有 99.88%检测到 IgG 抗 SARS-CoV-2 刺突蛋白。在较年轻的受试者（<30 岁的中位数 IgG 值为 807 UA/mL，>60 岁的中位数 IgG 值为 429 UA/mL；p<0.001）和有先前 COVID-19 病史的受试者（中位数 IgG 值为 1284 UA/mL，无先前 COVID-19 病史的受试者为 574 UA/mL；p<0.001）中观察到更高的 IgG 值。
即使在现实环境中，BNT162b2 也能有效诱导抗 SARS-CoV-2 抗体。在有先前记录的 SARS CoV2 感染的工作人员中观察到更高的抗体滴度证实了在疫苗短缺的情况下，仅接种一剂 BNT162b2 的可能性。
